NanoViricides, Inc. (NYSE‑American: NNVC) announced on February 10 2026 that it has filed an application with the U.S. Food and Drug Administration for Orphan Drug Designation (ODD) for its experimental antiviral NV‑387 as a treatment for measles.
The ODD application, submitted to the FDA’s Office of Orphan Products Development, seeks to secure incentives such as tax credits for qualified clinical trials, exemption from certain user fees, and the potential for seven years of market exclusivity following approval.
If granted, the designation would position NV‑387 as a first‑in‑class broad‑spectrum antiviral for measles, a disease that currently has no approved drug therapy and has seen a surge in cases in the United States. The filing marks a significant regulatory step toward commercializing the company’s host‑mimetic platform in a high‑need orphan indication.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.